Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing: Findings From the BabySeq Study

Brittan Armstrong1, Kurt D. Christensen2,3, Casie A. Genetti4, Richard B. Parad3,5, Jill Oliver Robinson1, Carrie L. Blout Zawatsky6,7,8,9, Bethany Zettler6, Alan H. Beggs3,4,10, Ingrid A. Holm3,4,10, Robert C. Green3,6,8,10, Amy L. McGuire1, Hadley Stevens Smith1† and Stacey Pereira1*† The BabySeq Project Team

1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, United States, 2PRecisOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, MA, United States, 5Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, United States, 6Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States, 7Medical and Population Genetics, The Broad Institute, Cambridge, MA, United States, 8Ariadne Labs, Boston, MA, United States, 9The MGH Institute of Health Professions, Boston, MA, United States, 10The Broad Institute of MIT and Harvard, Cambridge, MA, United States

Introduction: With increasing utility and decreasing cost of genomic sequencing, augmentation of standard newborn screening (NBS) programs with newborn genomic sequencing (nGS) has been proposed. Before nGS can be integrated into newborn screening, parents’ perspectives must be better understood.

Objective: Using data from surveys administered to parents of healthy newborns who were enrolled in the BabySeq Project, a randomized clinical trial of nGS alongside NBS, this paper reports parents’ attitudes regarding population-based NBS and nGS assessed 3 months after results disclosure.

Methods: Parental attitudes regarding whether all newborns should receive, and whether informed consent should be required for, NBS and nGS, as well as whether nGS should be mandated were assessed using 5-point scales from strongly disagree (=1) to strongly agree (=5). Parents’ interest in receiving types of results from nGS was assessed on a 5-point scale from not at all interested (=1) to very interested (=5). Survey responses were analyzed using Fisher’s exact tests, paired t-tests, and repeated measures ANOVA.

Results: At 3 months post-disclosure, 248 parents of 174 healthy newborns submitted a survey. Support for every newborn receiving standard NBS (mean 4.67) was higher than that for every newborn receiving nGS (mean 3.60; p < 0.001). Support for required informed consent for NBS (mean 3.44) was lower than that for nGS (mean 4.27, p < 0.001). Parents’ attitudes toward NBS and nGS were not significantly associated with self-reported political orientation. If hypothetically receiving nGS outside of the BabySeq Project, most parents reported being very interested in receiving information on their baby’s risk of developing a disease in childhood that can be prevented, treated, or cured...
INTRODUCTION

Since starting in the 1960s as a single screening test for phenylketonuria (PKU), developed by Dr. Robert Guthrie, newborn screening (NBS) has expanded in the United States into an extremely successful mandated public health program (Koppaka 2011; CDC 2020; Baby’s First Test 2021). While there are differences between states on the number and types of conditions that are screened, most states use a similar approach to mandating newborn screening, including an opt-out policy that does not require parental informed consent (Lewis and Botkin 2019). Current state-based programs can use tandem mass spectrometry to screen for over 50 different conditions to allow for presymptomatic detection, diagnosis, and treatment of conditions for which early intervention can reduce morbidity, mortality, and the social burden of disease (Cipriano et al., 2007; Therrell et al., 2015; Johnson and Wile 2017).

Building on the established success of NBS programs, some have proposed that there could be even greater public health impact if genomic sequencing (GS) were incorporated alongside current screening modalities (Genetic Alliance and District of Columbia Department of Health 2010; Groft et al., 2017). Increases in the speed and affordability of GS have rendered it a feasible option for consideration as a population-based screening tool (Groft et al., 2017). The addition of newborn GS (nGS) to NBS programs would enable screening for more conditions than current methods alone, with the potential to benefit more families (Berg and Powell 2015; Wojcik et al., 2021). A study comparing screening results between nGS by exome sequencing and standard public health dried blood spot NBS found that the two modalities provided complementary information, with exome sequencing identifying genetic risk for conditions not detected through standard NBS in 9.4% of sequenced newborns (Wojcik et al., 2021). Additionally, although genomic sequencing has not been found to be adequately sensitive or specific to be an appropriate stand-alone screening test, combining standard NBS with nGS could increase the specificity of NBS and reduce the rates of false positives (Bodian et al., 2016; Adhikari et al., 2020; Wojcik et al., 2021). In the same study comparing nGS and standard NBS results, nine infants were standard NBS positive but negative on exome sequencing. Seven of these infants were determined to be falsely positive on standard NBS (Wojcik et al., 2021).

(86.8%) and their risk of developing a disease during adulthood that can be prevented, treated, or cured (84.6%).

Discussion: Parents’ opinions are crucial to inform design and delivery of public health programs, as the success of the program hinges on parents’ trust and participation. To accommodate parents’ preferences without affecting the current high participation rates in NBS, an optional add-on consent to nGS in addition to NBS may be a feasible approach. Trial Registration ClinicalTrials.gov Identifier: NCT02422511.

Keywords: newborn screening (NBS), newborn sequencing, genomic sequencing, ELSI, ethics, exome sequencing, newborn genomic sequencing

MATERIALS AND METHODS

Study Participants and Design

The BabySeq Project is a series of randomized clinical trials designed to assess the medical, behavioral, and economic impact of nGS on infant care. The full study design of the first trial, from which we report results here, has been previously published (Holm et al., 2018). In the initial trial, two cohorts of parents and newborns were recruited to participate: parents with newborns admitted to the intensive care units (ICUs) at Brigham and Women’s Hospital (BWH), Massachusetts General Hospital, and Boston’s Children’s Hospital; and parents with apparently healthy newborns admitted to the BWH Well Baby Nursery. Each family was randomly assigned to receive either the standard NBS and a detailed family history report only (control group), or the same plus their infant’s exome sequencing report (nGS group). The exome sequencing report included monogenic disease risk results, i.e., pathogenic or likely pathogenic variants in approximately 1000 genes associated with actionable or non-
actionable childhood-onset conditions. Carrier status for recessive conditions was also returned. Monogenic disease risk results on highly actionable adult-onset conditions with available prevention strategies or treatment options that could impact outcome (as per the ACMG SF v2.0 list), as well as pharmacogenomic variants relevant during childhood, were also returned (Kalia et al., 2017). Adult-onset conditions were not included in the original study protocol but were later added in response to ethical concerns that arose around withholding actionable findings that may benefit the child by benefiting the parents or other family members (Holm et al., 2019). For participants enrolled after the protocol change, accepting results on actionable adult-onset conditions was a condition for enrollment. Participants who were enrolled prior to the change were contacted and given the option to consent to receive results related to adult-onset conditions (Holm et al., 2019). Reports were disclosed to families by a genetic counselor associated with the study before the reports were integrated into the electronic medical record and sent to pediatricians. Throughout the study, parents were surveyed on their experiences and their perspectives on the value of nGS. Surveys were administered at baseline, immediately post-disclosure, 3 months post-disclosure, and 10 months post-disclosure.

While the initial protocol involved limited recruitment of parents whose infants were in the ICUs, here we present findings only from surveys administered to parents enrolled from the healthy baby cohort, as this group is likely to be most representative of the general population of parents for whom population-based screening via nGS, to augment NBS, would be relevant. At baseline and 3 months post-disclosure, we assessed parental attitudes regarding whether every baby should receive NBS and GS at birth, whether informed consent should be required for these tests, and whether the state should require all newborns to receive GS at birth. We focus here on post-disclosure responses, as baseline survey results have been reported elsewhere, and this allows parents’ responses to be informed by their participation in the study (Pereira et al., 2019). Further, we examine attitudes assessed at 3 months post-disclosure regarding the types of results parents would want to receive from GS.

Available data from both parents of a newborn from the first trial were included in the analytic data set, and missing values were not imputed. Baylor College of Medicine’s Institutional Review Board (IRB), The Partners (now Mass General Brigham) Human Research Committee, and Boston Children’s IRB approved all aspects of the BabySeq Project. This trial is registered at ClinicalTrials.gov (NCT02422511). The data supporting the assertions of this article will be made available by the authors upon request.

Measures
Parental attitudes regarding whether all newborns should receive, and whether informed consent should be required for, NBS and nGS, as well as whether nGS should be mandated, were assessed using five items in both the baseline and the 3-month post-disclosure surveys. This section of each survey began with a description of NBS and nGS. Novel survey items were designed to assess whether parents’ agreed or disagreed with the following statements: 1) every newborn should receive standard NBS, 2) parental informed consent should be required for standard NBS, 3) every newborn should receive genomic sequencing, 4) parental informed consent should be required for genomic sequencing of a newborn, and 5) the state should require that all newborns receive genomic sequencing. Responses were collected on a 5-point Likert-type scale (“agreement scale”) from strongly disagree (=1) to strongly agree (=5).

Additionally, all parents were asked at 3 months post-disclosure how interested they would be in receiving the following types of information about their baby outside of the BabySeq Project, for example with their doctor or via a third-party service as a non-research participant. Options included: 1) diseases that develop during childhood that can be prevented, treated or cured (i.e., actionable); 2) diseases that develop during childhood that can NOT be prevented, treated, or cured, (i.e., non-actionable); 3) diseases that develop during adulthood that can be prevented, treated, or cured; 4) diseases that develop during adulthood that can NOT be prevented, treated, or cured; 5) carrier status, and 6) variants of uncertain significance (VUSs). Carrier status was defined for parents as “information about genetic changes that my baby may have that would not cause disease in my baby but that he/she could potentially pass on to his or her own future children, or that could affect my other children.” A VUS was defined for parents as “information that the researchers or doctors have not seen before or do not fully understand.” For each type of information, parents were asked to indicate their interest on a 5-point Likert-type scale (“interest scale”) from not at all interested (=1) to very interested (=5).

If a parent agreed or strongly agreed that every newborn should receive GS at 3 months post-disclosure, they were asked to indicate whether results in each of the categories described above (actionable and non-actionable childhood onset conditions, actionable and non-actionable adult-onset conditions, carrier status, and VUS) should be returned to parents, with multiple selections possible. This question was designed to assess parents’ views on which results they felt were appropriate to include in screening reports to all newborns parents after mandated nGS screening, as this may differ from the types of results they would want for their own child (asked of all parents, as described in the previous paragraph).

We collected information about parents’ demographic characteristics at baseline. Parents’ political orientation was measured at 3 months post-disclosure using the 11-point political orientation scale from 0 to 10 with labels of Liberal (≤0), Moderate (=5), and Conservative (=10) (Kroh 2007).

Data Analysis
Descriptive statistics were calculated for parents’ demographic characteristics (at baseline and 3 months post-disclosure) and survey responses at 3 months post-disclosure. Responses to the 5-point agreement and interest scales were analyzed using Wilcoxon rank sum tests to compare parents’ level of agreement with statements or interest in receiving various types of information from genomic sequencing between parents of families who were randomized to the control and
TABLE 1 | Demographic characteristics of parents who completed baseline and 3 months post-disclosure surveys.

|                        | Control (n = 106) | nGS (n = 142) | Total (n = 248) | p-value |
|------------------------|-------------------|--------------|----------------|---------|
| Gender                 |                   |              |                |         |
| Female                 | 62 (58.5%)        | 74 (52.1%)   | 136 (54.8%)    | 0.318   |
| Male                   | 44 (41.5%)        | 68 (47.9%)   | 112 (45.2%)    |         |
| Race                   |                   |              |                | 0.299   |
| Asian                  | 8 (8.1%)          | 18 (14.1%)   | 26 (11.5%)     |         |
| Black or African American | 4 (4.0%)       | 2 (1.6%)     | 6 (2.6%)       |         |
| More than one race     | 4 (4.0%)          | 2 (1.6%)     | 6 (2.6%)       |         |
| Other                  | 3 (3.0%)          | 2 (1.6%)     | 5 (2.2%)       |         |
| White                  | 80 (80.8%)        | 104 (81.2%)  | 184 (81.1%)    |         |
| Ethnicity              |                   |              |                | 0.098   |
| Non-Hispanic           | 82 (90.1%)        | 115 (95.8%)  | 197 (93.4%)    |         |
| Hispanic or Latino     | 9 (9.9%)          | 5 (4.2%)     | 14 (6.6%)      |         |
| Education level        |                   |              |                | 0.892   |
| Less than Bachelor’s   | 7 (6.6%)          | 10 (7.0%)    | 17 (6.9%)      |         |
| Bachelor’s or higher   | 99 (93.4%)        | 132 (93.0%)  | 231 (93.1%)    |         |
| Household income       |                   |              |                | 0.334   |
| $0–$99,999             | 18 (17.1%)        | 19 (13.7%)   | 37 (15.2%)     |         |
| ≥ $100,000–199,999     | 47 (44.8%)        | 54 (38.8%)   | 101 (41.4%)    |         |
| ≥ $200,000             | 40 (38.1%)        | 66 (47.5%)   | 106 (43.4%)    |         |
| Patient is parents’ first child |         |              |                | 0.133   |
| No                     | 48 (50.5%)        | 53 (40.5%)   | 101 (44.7%)    |         |
| Yes                    | 47 (49.5%)        | 78 (59.5%)   | 125 (55.3%)    |         |
| Monogenic disease risk finding |       |              |                |         |
| No monogenic disease risk | N/A             | 127 (89.4%)  | 127 (89.4%)    | N/A     |
| Monogenic disease risk finding |       |              |                |         |
| N/A                    | 15 (10.6%)        | 15 (10.6%)   |              | N/A     |

nGS, newborn genomic sequencing. NA, not applicable.

nGS groups. For each attitude question asked at 3 months post-disclosure, we used paired sample t-tests to compare parents’ responses regarding NBS to those regarding nGS. Additionally, attitudes assessed at 3-month post-disclosure were analyzed on the 5-point agreement scale by randomization arm and political orientation using Fisher’s exact tests. To facilitate analysis, we combined responses on the political orientation scale to create three categories: liberal (0–3 on original scale), moderate (4–6), or conservative (7–10). We used repeated measures analysis of variance (ANOVA) to assess the effect of randomization arm on parents’ attitudes regarding whether every newborn should receive each test at birth, whether informed consent should be required for each test, and whether the state should require that all newborns receive genomic sequencing at birth from baseline to 3 months post-disclosure. For ANOVA, survey responses on the 5-point agreement scale were combined for “disagree” and “strongly disagree” (=1) and “agree” and “strongly agree” (=3) and analyzed on a 3-point scale with neither agree nor disagree as the midpoint (=2).

RESULTS

A total of 406 parents of 257 healthy newborns were enrolled in the healthy baby cohort and responded to demographic questions in the baseline survey (Pereira et al., 2019). Among these parents, 248 parents of 174 healthy newborns also submitted a survey at 3 months post-disclosure. Demographic characteristics did not differ between parents who responded at baseline and who responded at 3 months post-disclosure, except for educational attainment; a higher proportion of parents who responded at both time points had a bachelor’s degree or higher (93%), compared to those who only responded at baseline (86%; p = 0.028). Table 1 presents self-reported characteristics of parents who responded at 3 months post-disclosure. Thirty parents who responded to the 3 months post-disclosure survey did not respond to the baseline survey, and therefore their demographic characteristics are not available.

Parental Attitudes Regarding Standard NBS and nGS

Table 2 presents parents’ attitudes regarding standard newborn screening and newborn genomic sequencing by study arm at 3 months post-disclosure. A majority of parents in both the control arm (96/122, 78.7%) and in the nGS arm (115/162, 71.0%) strongly agreed that every newborn should receive NBS. There was not a statistically significant interaction between the effect of study arm and time on agreement that every newborn should receive NBS. There was not a statistically significant interaction between the effect of study arm and time on agreement that every newborn should receive nGS (mean 3.67) was higher than that every newborn should receive GS (mean 3.60; p < 0.001). At 3 months post-disclosure, 18.5% (23/124) of parents in the control arm and 16.7% (27/162) of parents in the nGS arm strongly agreed that every newborn should receive nGS. There was no statistically significant interaction between study arm and time on agreement that every newborn should receive nGS (F(1, 252) = 0.66, p = 0.416). Parents’ average agreement that informed consent should be required to perform NBS (mean 3.44) was lower than that for
nGS (mean 4.27, p < 0.001). At 3 months post-disclosure, 29.0% (36/124) of parents in the control arm and 26.5% (43/162) of parents in the nGS arm strongly agreed that parental informed consent should be required for NBS, while 49.2% (61/124) of parents in the control arm and 44.7% (72/161) of parents in the nGS arm strongly agreed that parental informed consent should be required for nGS. There was not a statistically significant interaction between study arm and time on agreement that the state should require that all newborns receive genomic sequencing at birth. There was not a statistically significant interaction between study arm and self-reported political orientation (Table 3).

## Parent Preferences on Results

At 3 months post-disclosure, parents indicated their interest in receiving several possible types of GS results for their baby if their baby were to receive GS outside the BabySeq Project (Table 4). A majority of parents reported being very interested in receiving information on their baby’s risk of developing a disease in childhood that can be prevented, treated, or cured (86.8%); risk of developing a disease during adulthood that can NOT be prevented, treated, or cured (84.6%); and carrier status (70.8%). Only 42.0% of parents reported being very interested in receiving VUS results, and only 47.7% reported being very interested in learning their baby’s risk of developing a disease during adulthood that can NOT be prevented, treated, or cured. There were no differences in interest levels for receiving any result type between the control and nGS group (all p > 0.144).

Among parents who strongly agreed or agreed that every newborn should receive nGS at 3 months post-disclosure (n = 167), the most frequently selected categories of findings that should be returned to parents were actionable findings in childhood (98.8%) and adulthood (94.0%; Figure 1).

### Table 2: Parents’ attitudes regarding standard newborn screening and newborn genomic sequencing by study arm.

| Statement                                                                 | Control | nGS | Total | p-value |
|--------------------------------------------------------------------------|---------|-----|-------|---------|
| Every newborn should receive standard newborn screening                   |         |     |       |         |
| Strongly disagree                                                        | 0 (0.0%)| 1 (0.6%)| 1 (0.4%)|         |
| Disagree                                                                 | 1 (0.8%)| 2 (1.2%)| 3 (1.1%)|         |
| Neither agree nor disagree                                               | 4 (3.3%)| 7 (4.3%)| 11 (3.9%)|         |
| Agree                                                                    | 21 (17.2%)| 37 (22.8%)| 58 (20.4%)|         |
| Strongly agree                                                           | 96 (78.7%)| 115 (71.0%)| 211 (74.3%)|         |
| Every newborn should receive genomic sequencing                           |         |     |       |         |
| Strongly disagree                                                        | 3 (2.4%)| 7 (4.3%)| 10 (3.5%)|         |
| Agree                                                                    | 10 (8.1%)| 14 (8.6%)| 24 (8.4%)|         |
| Neither agree nor disagree                                               | 43 (34.7%)| 42 (25.9%)| 85 (29.7%)|         |
| Agree                                                                    | 45 (36.3%)| 72 (44.4%)| 117 (40.9%)|         |
| Strongly agree                                                           | 23 (18.5%)| 27 (16.7%)| 50 (17.5%)|         |
| The state should require that all newborns receive genomic sequencing at birth |         |     |       |         |
| Strongly disagree                                                        | 14 (11.4%)| 14 (8.8%)| 28 (9.9%)|         |
| Agree                                                                    | 23 (18.7%)| 39 (24.5%)| 62 (22.0%)|         |
| Neither agree nor disagree                                               | 47 (38.2%)| 52 (32.7%)| 99 (35.1%)|         |
| Parental informed consent should be required for standard newborn screening |         |     |       |         |
| Strongly disagree                                                        | 9 (7.3%)| 19 (11.7%)| 28 (9.8%)|         |
| Disagree                                                                 | 28 (22.8%)| 41 (25.8%)| 69 (24.5%)|         |
| Neither agree nor disagree                                               | 18 (14.5%)| 30 (18.5%)| 48 (16.8%)|         |
| Agree                                                                    | 33 (26.6%)| 44 (27.2%)| 77 (26.9%)|         |
| Parental informed consent should be required for genomic sequencing       |         |     |       |         |
| Strongly disagree                                                        | 2 (1.6%)| 4 (2.5%)| 6 (2.1%)|         |
| Disagree                                                                 | 3 (2.4%)| 6 (3.7%)| 9 (3.2%)|         |
| Neither agree nor disagree                                               | 7 (5.6%)| 12 (7.5%)| 19 (6.7%)|         |
| Agree                                                                    | 51 (41.1%)| 67 (41.6%)| 118 (41.4%)|         |
| Strongly agree                                                           | 61 (49.2%)| 72 (44.7%)| 133 (46.7%)|         |
TABLE 3 | Parents’ attitudes regarding newborn screening and genomic sequencing by political orientation.

| Attitude                                                                 | Liberal | Moderate | Conservative | p-value |
|-------------------------------------------------------------------------|---------|----------|--------------|---------|
| Every newborn should receive standard newborn screening                  | n = 161 | n = 79   | n = 30       | 0.187   |
| Strongly disagree                                                       | 1 (0.6%)| 0 (0.0%) | 0 (0.0%)     | —       |
| Disagree                                                                | 2 (1.2%)| 1 (1.3%) | 0 (0.0%)     | —       |
| Neither agree nor disagree                                              | 4 (2.5%)| 3 (3.8%) | 3 (10.0%)    | —       |
| Agree                                                                   | 29 (18.5%) | 13 (16.5%) | 10 (33.3%)  | —       |
| Strongly agree                                                          | 125 (77.6%) | 62 (78.5%) | 17 (66.7%)  | —       |
| Every newborn should receive genomic sequencing                          | n = 163 | n = 79   | n = 30       | 0.448   |
| Strongly disagree                                                       | 5 (3.1%)| 4 (5.1%) | 0 (0.0%)     | —       |
| Disagree                                                                | 18 (11.0%) | 6 (7.6%) | 0 (0.0%)     | —       |
| Neither agree nor disagree                                              | 49 (30.1%) | 22 (27.8%) | 10 (33.3%)  | —       |
| Agree                                                                   | 67 (41.1%) | 30 (38.0%) | 13 (43.3%)  | —       |
| Strongly agree                                                          | 24 (14.7%) | 17 (21.5%) | 7 (23.3%)    | —       |
| The state should require that all newborns receive genomic sequencing at birth | n = 163 | n = 79   | n = 30       | 0.354   |
| Strongly disagree                                                       | 10 (6.1%)| 9 (11.4%) | 3 (10.0%)    | —       |
| Disagree                                                                | 40 (24.5%) | 20 (25.3%) | 7 (23.3%)    | —       |
| Neither agree nor disagree                                              | 66 (40.5%) | 20 (25.3%) | 9 (30.0%)    | —       |
| Agree                                                                   | 34 (20.9%) | 19 (24.1%) | 7 (23.3%)    | —       |
| Strongly agree                                                          | 13 (8.0%) | 11 (13.9%) | 4 (13.3%)    | —       |
| Parental informed consent should be required for standard newborn screening | n = 163 | n = 79   | n = 30       | 0.359   |
| Strongly disagree                                                       | 17 (10.4%) | 7 (9.9%)  | 2 (6.7%)     | —       |
| Disagree                                                                | 34 (20.9%) | 14 (17.7%) | 5 (16.7%)    | —       |
| Neither agree nor disagree                                              | 30 (18.4%) | 7 (9.9%)  | 8 (26.7%)    | —       |
| Agree                                                                   | 39 (23.9%) | 24 (30.4%) | 9 (30.0%)    | —       |
| Strongly agree                                                          | 43 (26.4%) | 27 (34.2%) | 6 (20.0%)    | —       |
| Parental informed consent should be required for genomic sequencing of a newborn | n = 163 | n = 79   | n = 30       | 0.247   |
| Strongly disagree                                                       | 4 (2.5%) | 1 (1.3%)  | 1 (3.3%)     | —       |
| Disagree                                                                | 5 (3.1%) | 3 (3.8%)  | 1 (3.3%)     | —       |
| Neither agree nor disagree                                              | 13 (8.0%) | 3 (3.8%)  | 1 (3.3%)     | —       |
| Agree                                                                   | 62 (38.0%) | 32 (40.5%) | 19 (63.3%)  | —       |
| Strongly agree                                                          | 79 (48.5%) | 40 (50.6%) | 8 (26.7%)    | —       |

DISCUSSION

In this analysis of survey responses from parents of healthy newborns in the BabySeq Project, parents were more supportive of every newborn receiving NBS than receiving nGS. We found no significant difference in nGS support between parents in the control arm and parents who had experienced receiving nGS results for their newborn, and results suggest that the experience of receiving nGS results did not affect parents’ attitudes over time. While a majority of parents supported the notion that every newborn should receive GS, only a minority thought that the state should require nGS. Additionally, a larger proportion of parents agreed that parental informed consent should be required for nGS than for standard NBS. Previous studies examining parent attitudes toward standard NBS and nGS have also reported parent concern about not requiring informed consent for nGS, increased parent support for standard NBS compared to nGS, and disagreement between parents about which results should be reported (Bombard et al., 2014; Joseph et al., 2016; Lewis et al., 2018; Moultie et al., 2020). Though most parents indicated they would be interested in receiving all available result types if their baby received GS outside the BabySeq Project, enthusiasm varied among result types.

NGS in newborns may provide health benefits and information complementary to standard NBS. A previously published study from the BabySeq Project showed that families experienced no sustained negative psychosocial effects from participating in the GS process or receiving results, a concern frequently raised in the discussion surrounding the addition of nGS (Pereira et al., 2021; Wojcik et al., 2021). However, even highly successful programs like standard NBS can come under scrutiny if policies are not acceptable to parents (National Institute of Child Health and Human Development, 2017). It is critical to consider parent buy-in before implementing policies that impact NBS programs; not doing so may risk negatively affecting parent trust, participation, and thus the overall success of the program.

Even among our group of parents who had enough interest in nGS to volunteer to participate in the BabySeq Project, a majority of parents thought informed consent should be required for nGS and many were still hesitant about adding nGS to current state mandated NBS programs. Considering that parents who participated in the BabySeq Project may likely be more supportive of nGS than the average parent, our study results suggest that implementing nGS without addressing parental concerns could create parent backlash. Another study comparing parent views on nGS vs standard NBS in Canada came to a similar conclusion after finding parents were significantly less willing to participate in a NBS program that included whole genome or exome sequencing (Bombard et al., 2014). Notably, a majority of our parents thought that informed consent should also be required for standard NBS, which is not legally required in most states. It may be possible that, although...
TABLE 4 | Parents’ attitudes regarding desired results from newborn genomic sequencing by study arm.

|                           | Control | nGS | Total | p-value |
|---------------------------|---------|-----|-------|---------|
| **My baby’s risk of developing a disease during childhood that can be prevented, treated, or cured** |         |     |       |         |
| Not at all interested     | 1 (0.8%) | 0 (0.0%) | 1 (0.3%) | —       |
| Not very interested       | 1 (0.8%) | 1 (0.6%) | 2 (0.7%) | —       |
| Neutral                   | 4 (3.2%) | 5 (3.1%) | 9 (3.1%) | —       |
| Somewhat interested       | 11 (8.9%) | 15 (9.2%) | 26 (9.1%) | —       |
| Very interested           | 107 (86.3%) | 142 (87.1%) | 249 (86.8%) | —       |
| **My baby’s risk of developing a disease during childhood that can NOT be prevented, treated, or cured** |         |     |       |         |
| Not at all interested     | 7 (5.6%) | 5 (3.1%) | 12 (4.2%) | —       |
| Not very interested       | 9 (7.2%) | 9 (5.5%) | 18 (6.2%) | —       |
| Neutral                   | 15 (12.0%) | 17 (10.4%) | 32 (11.1%) | —       |
| Somewhat interested       | 35 (28.0%) | 45 (27.6%) | 80 (27.8%) | —       |
| Very interested           | 59 (47.2%) | 87 (53.4%) | 146 (50.7%) | —       |
| **My baby’s risk of developing a disease during adulthood that can be prevented, treated, or cured** |         |     |       |         |
| Not at all interested     | 1 (0.8%) | 0 (0.0%) | 1 (0.4%) | —       |
| Not very interested       | 1 (0.8%) | 2 (1.2%) | 3 (1.1%) | —       |
| Neutral                   | 3 (2.4%) | 4 (2.5%) | 7 (2.5%) | —       |
| Somewhat interested       | 14 (11.3%) | 19 (11.8%) | 33 (11.6%) | —       |
| Very interested           | 105 (84.7%) | 136 (84.5%) | 241 (84.6%) | —       |
| **My baby’s risk of developing a disease during adulthood that can NOT be prevented, treated, or cured** |         |     |       |         |
| Not at all interested     | 7 (5.6%) | 10 (6.2%) | 17 (6.0%) | —       |
| Not very interested       | 18 (14.5%) | 8 (5.0%) | 26 (9.1%) | —       |
| Neutral                   | 11 (8.9%) | 19 (11.8%) | 30 (10.5%) | —       |
| Somewhat interested       | 34 (27.4%) | 42 (26.1%) | 76 (26.7%) | —       |
| Very interested           | 54 (43.5%) | 82 (50.9%) | 136 (47.7%) | —       |
| **Carrier status**        |         |     |       |         |
| Not at all interested     | 2 (1.6%) | 2 (1.2%) | 4 (1.4%) | —       |
| Not very interested       | 2 (1.6%) | 2 (1.2%) | 4 (1.4%) | —       |
| Neutral                   | 10 (8.0%) | 7 (4.3%) | 17 (5.9%) | —       |
| Somewhat interested       | 24 (19.2%) | 35 (21.5%) | 59 (20.5%) | —       |
| Very interested           | 87 (69.6%) | 117 (71.8%) | 204 (70.8%) | —       |
| **Variants of uncertain significance** |         |     |       |         |
| Not at all interested     | 4 (3.2%) | 9 (5.6%) | 13 (4.5%) | —       |
| Not very interested       | 13 (10.4%) | 10 (6.2%) | 23 (8.0%) | —       |
| Neutral                   | 25 (20.0%) | 33 (20.5%) | 58 (20.3%) | —       |
| Somewhat interested       | 30 (24.0%) | 42 (26.1%) | 72 (25.2%) | —       |
| Very interested           | 53 (42.4%) | 67 (41.6%) | 120 (42.0%) | —       |

FIGURE 1 | Attitudes toward results types to be returned to parents if every newborn received GS. Only asked if parent agreed or strongly agreed that every newborn should receive GS (n = 167). Respondents could select multiple options.
parents may ideally want an informed consent process, they tolerate a lack of informed consent because such a strong majority feel that every newborn should receive standard NBS. However, nGS does not share this same level of support in our study sample.

One approach to accommodate parents’ preferences while preserving participation in current newborn screening programs would be for nGS to be an optional addition to state mandated NBS that requires explicit informed consent. This optional add-on consent model gives the opportunity for counseling on GS screening to ensure parents understand the capacity, utility, and limitations of GS. This approach was successfully implemented for expanded NBS using tandem mass spectrometry. For example, when Massachusetts added mass spectrometry to their NBS program as an optional add-on program in 1999, 98% of parents chose to participate, prompting other states to expand their newborn screening programs (Marsden 2003). More recent studies examining newborn genetic screening for SMA and Duchenne Muscular Dystrophy have also used this model and experienced high parent participation rates (Kraszewski et al., 2017; Parad et al., 2021). While an optional add-on model could help demonstrate the health benefits of GS screening without compromising existing mandated public health programs, it induces the burden of additional informed consent and documentation on hospital staff. One California study examining the introduction of mass spectrometry to NBS that required informed consent demonstrated significant burden of documentation, resulting in many families not being offered the additional screening (Feuchtbaum et al., 2007). If hospital systems are not prepared to incur the burden of additional screening, increased documentation, follow-up and parent counseling that would be required to incorporate nGS into NBS, the addition of these programs may fail to produce the desired result and overall compromise parent satisfaction and trust. There are also concerns that requiring informed consent for any portion of the NBS may reduce overall participation rates (Davis et al., 2006; Feuchtbaum et al., 2007).

Interestingly, while other studies have found some association between political orientation and interest in genomic sequencing (Dodson et al., 2015), political orientation was not significantly associated with opinions of whether states should require GS in our study. This suggests that it may be possible to garner bipartisan support for policies regarding nGS. Finally, there is the issue of what results are considered ethical to return and which results parents want may pose challenges if whole genome or exome sequencing is used for nGS, as parents may be able to invoke a legal right to the entirety of their child’s genomic data.

Our results should be considered within the limitations of our study. Study participants were parents willing to participate in a genomics study from three hospitals in the Boston, Massachusetts area. As such, opinions may differ significantly between study participants and the general population. It is also important to note that our study demographics are not representative of the general US population, with a high proportion of non-Hispanic white individuals, high household income, and high educational attainment. Representative surveys are warranted to provide more generalizable information suited to inform federal and state policy discussions. The second iteration of the BabySeq Project, BabySeq2, currently underway, will prioritize the inclusion of a more racially, ethnically, and geographically diverse cohort of families (https://www.genomes2people.org/research/babyseq/) and will provide additional data on parents’ attitudes. Finally, our surveys were not designed to capture nuanced views; it is possible that parents may have expressed more tempered attitudes toward screening and results types in interviews or focus groups.

Currently, the NBS program has parents’ trust and near universal participation. Any policies created to expand the NBS program to include nGS should strive to protect this trust and preserve parent support by considering parent values. We propose that should nGS be added to current NBS programs, parent values could be respected if it were initially added as an optional supplemental screen that requires an informed consent process with preservation of the default mandatory NBS using traditional methods.

BABYSEQ TEAM MEMBERS

Pankaj B Agrawal, Alan H. Beggs, Wendi N. Betting, Ozge Ceyhan-Birsoy, Kurt D. Christensen, Dmitry Dukhovny, Shawn Fayer, Leslie A. Frankel, Casie A. Genetti, Chet Graham, Robert C. Green, Amanda M. Gutierrez, Maegan Harden, Ingrid A Holm, Joel B. Krier, Matthew S. Lebo, Kaitlyn B. Lee, Harvey L. Levy, Xingquan Lu, Kalotina Machini, Amy L. McGuire, Jaclyn B. Murry, Medha Naik, Tiffany T. Nguyen Dolphyn, Richard B. Parad, Hayley A. Peoples, Stacey Pereira, Devan Petersen, Uma Ramamurthy, Vivek Ramanathan, Heidi L. Rehm, Amy Roberts, Jill Oliver Robinson, Sergei Roumiantsev, Talia S. Schwartz, Hadley Stevens Smith, Tina K Truong, Grace E. VanNoy, Susan E. Waisbren, Timothy W. Yu, Carrie L Blout Zawatsky, Bethany Zettler.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by Baylor College of Medicine’s Institutional Review Board (IRB), The Partners (now Mass General Brigham) Human Research Committee, and Boston Children’s IRB. Participants provided written informed consent.

AUTHOR CONTRIBUTIONS

BA, SP, and HS designed the project and contributed to interpretation of the results. HS conducted the statistical analysis. BA took the lead in writing the first draft of the manuscript. SP and HS oversaw all aspects of the project. SP, BA, AM, JR, KC, and RP provided input on analysis. All authors contributed to the framing of the manuscript, revised the work critically for intellectual content, agreed to be named as authors, and agreed to be accountable for all aspects of the work.

FUNDING

This work was supported by grants U19-HD077671 (RG and AB) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Human Genome Research Institute of the NIH, and U01-TR003201 (RG and IH) from the National Center for Advancing Translational Sciences. RG was also supported by NIH grants R01-HG009922, OT2-OD026553, R01-HL143295. KC was supported by NIH grants K01-HG009173 and R01-HD090019. HS was supported by NIH grant K99-HG011491.

REFERENCES

Adhikari, A. N., Gallagher, R. C., Wang, Y., Currier, R. J., Amatuni, G., Bassaganyas, L., et al. (2020). The Role of Exome Sequencing in Newborn Screening for Inborn Errors of Metabolism. Nat. Med. 26, 1392–1397. doi:10.1038/s41591-020-0966-5

Baby’s First Test (2021). Newborn Screening 101. Available at: https://www.babysfirsttest.org/newborn-screening/screening-101 (Accessed May 26, 2021).

Berg, J. S., and Powell, C. M. (2015). Potential Uses and Inherent Challenges of Using Genome-Scale Sequencing to Augment Current Newborn Screening. Cold Spring Harb. Perspect. Med. 5 (12), a023150. doi:10.1101/cshperspect.a023150

Bodian, D. L., Klein, E., Iyer, R. K., Wong, W. S. W., Kohiyali, P., Stauffer, D., et al. (2016). Utility of Whole-Genome Sequencing for Detection of Newborn Screening Disorders in a Population Cohort of 1,696 Neonates. Genet. Med. 18 (3), 221–230. doi:10.1038/gim.2015.111

Bombard, Y., Miller, F. A., Hayeems, R. Z., Barg, C., Cressman, C., Carroll, J. C., et al. (2014). Public Views on Participating in Newborn Screening Using Genome Sequencing. Eur. J. Hum. Genet. 22 (11), 1248–1254. doi:10.1038/ejhg.2014.22

Botkin, J. R., Belmont, J. W., Berg, J. S., Berkman, B. E., Bombard, Y., Holm, I. A., et al. (2015). Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am. J. Hum. Genet. 97 (3), 501. doi:10.1016/j.ajhg.2015.07.013

CDC (2020). Newborn Screening. Available at: https://www.cdc.gov/ncbddd/features/newbornscreening-program/index.htm#:~:text=This%20project%20helps%20known%20newborns,be%20laboratory%20tests%20of%20SCAP (Accessed July 15, 2021).

Cipriano, L. E., Rupar, C. A., and Zaric, G. S. (2007). The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model. Value in Health 10 (2), 83–97. doi:10.1111/j.1524-4733.2006.00156.x

Davis, T. C., Humiston, S. G., Arnold, C. L., Bocchini, J. A., Bass, P. F., Krenn, E. M., 3rd, et al. (2006). Recommendations for Effective Newborn Screening Communication: Results of Focus Groups with Parents, Providers, and Experts. Pediatrics 117 (5 Pt 2), S326–S340. doi:10.1542/peds.2005-2633M

Dodson, D. S., Goldenberg, A. J., Davis, M. M., Singer, D. C., and Tarini, B. A. (2015). Parent and Public Interest in Whole-Genome Sequencing. Public Health Genomics 18 (3), 151–159. doi:10.1159/000375115

Feuchtbaum, L., Cunningham, G., and Sciotrino, S. (2007). Questioning the Need for Informed Consent: A Case Study of California’s Experience with a Pilot Newborn Screening Project. J. Empirical Res. Hum. Res. Ethics 2 (3), 3–14. doi:10.1525/ier.2007.2.3.3

Genetic Alliance and District of Columbia Department of Health (2010). Chapter 4 Newborn Screening. in Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals. Washington, DC: Genetic Alliance.

Goldenberg, A. J., Dodson, D. S., Davis, M. M., and Tarini, B. A. (2014). Parents’ Interest in Whole-Genome Sequencing of Newborns. Genet. Med. 16 (1), 78–84. doi:10.1038/gim.2013.76

Groß, S. C., Taruscio, D., and Posada de la Paz, M. (2017). Rare Diseases Epidemiology: Update and Overview. New York: Springer International Publishing.

Holm, L. A., McGuire, A., Pereira, S., Rehm, H., Green, R. C., and Beggs, A. H. (2019). Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights from the BabySeq Project. Pediatrics 143 (Suppl. 1), S37–S43. doi:10.1542/peds.2018-1099H

Holm, L. A., Agrawal, P. B., Agrawal, P. B., Ceyhan-Birsoy, O., Christensen, K. D., Fayer, S., et al. (2018). The BabySeq Project: Implementing Genomic Sequencing in Newborns. BMC Pediatr. 18 (1). 225. doi:10.1186/s12887-018-1200-1

Johnson, T., and Wile, M. (2017). State Newborn Health Screening Policies. Available at: https://www.ncsl.org/research/health/state-newborn-health-screening-policies.aspx (Accessed July 13, 2021).

Johnston, J., Lantos, J. D., Goldenberg, A., Chen, F., Parens, E., and Koenig, B. A. (2018). Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies. Hastings Cent. Rep. 48 (52), S2–S6. doi:10.1002/hast.874

Joseph, G., Chen, F., Harris-Wai, J., Puck, J. M., Young, C., and Koenig, B. A. (2016). Parental Views on Expanded Newborn Screening Using Whole-Genome Sequencing. Pediatrics 137, S36–S46. doi:10.1542/peds.2015-3731H

Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., et al. (2017). Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing. 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics. Genet. Med. 19 (2), 249–255. doi:10.1038/gim.2016.190

Koppaka, R. (2011). Ten Great Public Health Achievements for Teens. Pediatrics 128 (3), 619–623. doi:10.1542/peds.2015-3731H

Kraszewski, J. N., Kay, D. M., Stevens, C. F., Koval, C., Haser, B., Ortiz, V., et al. (2017). Pilot Study of Population-Based Newborn Screening for Spinal Muscular Atrophy in New York State. Genet. Med. 20 (6), 608–613. doi:10.1038/gim.2017.152

Kroh, M. (2007). Measuring Left-Right Political Orientation: The Choice of Response Format. Public Opin. Q. 71 (2), 204–220. doi:10.1093/poq/nfm009

Lewis, M. A., Stine, A., Paquin, R. S., Mansfield, C., Wood, D., Rini, C., et al. (2018). Parental Preferences toward Genomic Sequencing for Non-medically
Armstrong et al. Parents Attitudes Toward Newborn Sequencing

Lewis, M. H., and Botkin, J. R. (2019). "Newborn Screening in the United States: Ethical Issues," in The Oxford Handbook of Public Health Ethics. Editor A. C. Mastroianni (Oxford University Press), 653–664. doi:10.1093/oxfordhb/9780190245191.013.59

Lewis, T. (2019). 23 and Baby.

Marsden, D. (2003). Expanded Newborn Screening by Tandem Mass Spectrometry: the Massachusetts and New England Experience. Southeast Asian J. Trop. Med. Public Health 34 Suppl 3 (Suppl. 3), 111–114.

Moultrie, R. R., Paquin, R., Rini, C., Roche, M. L., Berg, J. S., Powell, C. M., et al. (2020). Parental Views on Newborn Next Generation Sequencing: Implications for Decision Support. Matern. Child. Health J. 24 (7), 856–864. doi:10.1007/s10995-020-02953-z

National Institute of Child Health and Human Development (2017). How many Newborns Are Screened in the united states? Available at: https://www.nichd.nih.gov/health/topics/newborn/conditioninfo/infants-screened (Accessed July 15, 2021).

Parad, R. B., Sheldon, Y., and Bhattacharjee, A. (2021). Implementation of Hospital-Based Supplemental Duchenne Muscular Dystrophy Newborn Screening (sDMDNBS): a Pathway to Broadening Adoption. Jns 7 (4), 77. doi:10.3390/jns7040077

Pereira, S., Robinson, J. O., Gutierrez, A. M., Petersen, D. K., Hsu, R. L., Lee, C. H., et al. (2019). Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics 143 (Suppl. 1), S6–S13. doi:10.1542/peds.2018-1099C

Pereira, S., Smith, H. S., Frankel, L. A., Christensen, K. D., Islam, R., Robinson, J. O., et al. (2021). Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project. JAMA Pediatr. 175 (11), 1132–1141. doi:10.1001/jamapediatrics.2021.2829

Ross, L. F., Saal, H. M., David, K. L., and Anderson, R. R. (2013). Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children. Genet. Med. 15 (3), 234–245. doi:10.1038/gim.2012.176

Tarini, B. A. (2021). The Effect of BabySeq on Pediatric and Genomic Research: More Than Baby Steps. JAMA Pediatr. 175 (11), 1107–1108. doi:10.1001/jamapediatrics.2021.2826

Therrell, B. L., Padilla, C. D., Loeber, J. G., Kneisser, I., Saadallah, A., Borrajo, G. J. C., et al. (2015). Current Status of Newborn Screening Worldwide: 2015. Semin. Perinatology 39, 171–187. doi:10.1053/j.semperi.2015.03.002

Timmermans, S., and Bucchinder, M. (2010). Patients-in-Waiting. J. Health Soc. Behav. 51 (4), 408–423. doi:10.1177/0022146510386794

Waisbren, S. E., Bäck, D. K., Liu, C., Kalia, S. S., Ringer, S. A., Holm, I. A., et al. (2015). Parents Are Interested in Newborn Genomic Testing during the Early Postpartum Period. Genet. Med. 17 (6), 501–504. doi:10.1038/gim.2014.139

Wojcik, M. H., Zhang, T., Ceyhan-Bissoy, O., Genetti, C. A., Lebo, M. S., Yu, T. W., et al. (2021). Discordant Results between Conventional Newborn Screening and Genomic Sequencing in the BabySeq Project. Genet. Med. 23 (7), 1372–1375. doi:10.1038/s41436-021-01146-5

Conflict of Interest: RG has received compensation for advising the following companies: AIA, Allelica, Embryome, Genomic Life, Grail, Humanity, Kneed Media, Meenta, Optum Labs, Plumcare, Verily, VinBigData; and is co-founder of Genome Medical.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Armstrong, Christensen, Genetti, Parad, Robinson, Blout Zawatsky, Zetlter, Beggs, Holm, Green, McGuire, Smith and Pereira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.